Hyperliquid Strategies completes business combination with Sonnet BioTherapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
December 2, 2025 4:30 PM ESTHyperliquid Strategies Common Stock Expected to Begin Trading on Nasdaq on Wednesday, December 3 Under the Ticker PURR
NEW YORK and PRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Hyperliquid Strategies Inc (HSI or the Company) and Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) (Sonnet) today announced the completion of the closing of the previously announced business combination among HSI, Sonnet and Rorschach I LLC (Rorschach), a newly-formed entity formed by an entity affiliated with Atlas Merchant Capital LLC (Atlas), an affiliate of Paradigm Operations LP (Paradigm), and additional sponsors (all together, the Sponsors), which was approved by Sonnets... More
